Found (3) clinical trials

This is a multi-centre study conducted in four countries. A total of 60 subjects with Alzheimer's disease who are on standard-of-care will be enrolled to receive one of 3 active HTL0018318 or placebo for a period of four weeks

The study will enroll 3 cohorts of 8 healthy subjects 55 and 80 years of age at the Clinical Pharmacology Unit (CPU) and 1 cohort of 12 AD subjects 55 and 80 years of age. Subjects in cohorts 1-3 will receive the study drug or placebo for 10 consecutive days ...

The purpose of this study is to assess the safety and tolerability of JNJ-63733657 following single ascending intravenous (IV) dose administration in healthy subjects (Part 1) and multiple ascending IV dose administrations in subjects with prodromal or mild Alzheimer's disease (AD) (Part 2).